Patterns of Physical Therapy Referral and Subsequent Attendance Among Childhood Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy at a Regional Childhood Cancer Survivorship Clinic

被引:0
|
作者
Kang, Lixin [1 ]
Kadan-Lottick, Nina S. [2 ]
Rotatori, Jaime [3 ]
Kujawski, Sophia E. [3 ]
Messerschmidt, Emily [4 ]
Auerbach, Claudia [3 ]
Balsamo, Lyn M. [3 ]
Lustberg, Maryam B. [5 ,7 ]
Ma, Xiaomei [1 ,6 ,7 ]
Rodwin, Rozalyn L. [3 ,7 ]
机构
[1] Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA
[2] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[3] Yale Sch Med, Dept Pediat, New Haven, CT USA
[4] Yale New Haven Hlth, Dept Rehabil Serv, New Haven, CT USA
[5] Yale Sch Med, Dept Med, New Haven, CT USA
[6] Yale Sch Med, Canc Outcomes Publ Policy & Effectiveness Res Ctr, New Haven, CT USA
[7] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA
基金
美国国家卫生研究院;
关键词
Physical therapy; Childhood cancer survivor; Chemotherapy-induced peripheral neuropathy; Motor neuropathy; MAINTENANCE THERAPY; CHILDREN; CARE; NURSES; INTERVENTION; ADOLESCENTS; LEUKEMIA; ACCESS; IMPACT;
D O I
10.1016/j.soncn.2024.151716
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Childhood cancer survivors are at risk for chemotherapy-induced peripheral neuropathy (CIPN). Physical therapy (PT) improves CIPN symptoms, but little is known about survivors' PT utilization. We described characteristics of survivors with >= grade 2 CIPN, investigated PT referral and attendance, and described characteristics of survivors who attended and did not attend PT. Methods: Childhood cancer survivors <21 years old at cancer diagnosis and >= 2 years posttherapy, living in the United States, evaluated at a regional survivorship clinic were included in this retrospective analysis if they had motor CIPN. Symptomatic CIPN (>= grade 2 by Common Terminology Criteria for Adverse Events) and PT referral/attendance were tabulated. Patient characteristics from the medical record, and neighborhood characteristics (retrieved using survivors' zip code from the National Neighborhood Data Archive) were described by group. Results: Among 91 survivors with CIPN (median 17.5 years old, 8.1 years postcancer diagnosis, 45.1% female), 35 (38.5%) had >= grade 2 CIPN. Survivors with >= grade 2 CIPN were 28.6% female, and 45.7% were <13 years old. Twenty-four (68.6%) survivors with >= grade 2 CIPN agreed to PT referral, and 15 (42.9%) attended PT. Among survivors who attended PT, 73.3% were <13 years old. Neighborhood characteristics of survivors included median percentage of adults without a high school diploma (6.7% PT attendees, 12.5% nonattendees), median percentage of adults who are foreign-born (11.5% PT attendees, 16.4% nonattendees), and median percentage of households with an annual income of <$15,000 (3.2% PT attendees, 6.5% nonattendees). Conclusions: While 68.6% of survivors with >= grade 2 CIPN were referred to PT, only 42.9% attended. Studies to better understand barriers to PT attendance and interventions to improve attendance are needed, especially in older survivors.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Association of Chemotherapy-Induced Peripheral Neuropathy with Diet Quality Among Post-Treatment Cancer Survivors
    Knoerl, Robert
    Ploutz-Snyder, Robert
    Smener, Liat
    Tofthagen, Cindy
    Zick, Suzanna
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2024, 76 (08): : 717 - 725
  • [32] CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IS ASSOCIATED WITH REDUCED EXECUTIVE FUNCTION IN CHEMOTHERAPY TREATED CANCER SURVIVORS
    McNeish, Brendan
    Hehir, Michael
    Dittus, Kim
    Redfern, Mark
    Rosano, Caterina
    Richardson, James
    Kolb, Noah
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S74 - S75
  • [33] Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors: A Single Institution Snapshot
    Teng, C.
    Vardy, J.
    Blinman, P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 45 - 45
  • [34] Survivor clinic attendance among pediatric- and adolescent-aged survivors of childhood cancer
    Daly, Ashley
    Lewis, Rebecca Williamson
    Vangile, Kristen
    Masker, Karen Wasilewski
    Effinger, Karen E.
    Meacham, Lillian R.
    Mertens, Ann C.
    JOURNAL OF CANCER SURVIVORSHIP, 2019, 13 (01) : 56 - 65
  • [35] Survivor clinic attendance among pediatric- and adolescent-aged survivors of childhood cancer
    Ashley Daly
    Rebecca Williamson Lewis
    Kristen Vangile
    Karen Wasilewski Masker
    Karen E. Effinger
    Lillian R. Meacham
    Ann C. Mertens
    Journal of Cancer Survivorship, 2019, 13 : 56 - 65
  • [36] Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer
    Kanda, K.
    Fujimoto, K.
    Mochizuki, R.
    Ishida, K.
    Lee, B.
    BMC CANCER, 2019, 19 (01)
  • [37] Chemotherapy-induced peripheral neuropathy in breast cancer survivors: Comparison of objective and subjective measures
    Bao, T.
    Kwon, A.
    Piulson, L.
    Chen, P.
    Li, Q.
    Patil, S.
    Seidman, A.
    Blinder, V.
    Vahdat, L.
    Zhi, W. I.
    Mao, J. J.
    CANCER RESEARCH, 2019, 79 (04)
  • [38] Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors
    Thomaier, Lauren
    Darst, Burcu F.
    Jewett, Patricia
    Hoffmann, Cody
    Brown, Katherine
    Makaram, Aditi
    Blaes, Anne
    Argenta, Peter
    Teoh, Deanna
    Vogel, Rachel, I
    GYNECOLOGIC ONCOLOGY, 2021, 163 (03) : 578 - 582
  • [39] Sensorimotor vs. endurance exercise in cancer survivors with chemotherapy-induced peripheral neuropathy
    Mueller, J.
    Wehrle, A.
    Kneis, S.
    Gollhofer, A.
    Bertz, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 42 - 43
  • [40] Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors
    Thomaier, Lauren
    Darst, Burcu
    Jewett, Patricia
    Hoffmann, Cody
    Brown, Katherine
    Makaram, Aditi
    Argenta, Peter
    Teoh, Deanna
    Blaes, Anne
    Vogel, Rachel
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S56 - S56